Actavis shells out $23 per share for Durata; deal valued at $616mm
In a move that significantly enhances its emerging infectious disease business, specialty pharmaco Actavis PLC is acquiring public Irish firm Durata Therapeutics Inc. for $23.00 in cash per share (a 75% premium), valuing the transaction at $616mm. Actavis will also issue Durata stockholders contingent value rights (CVRs) to receive up to $5.00 per share if certain regulatory and commercial milestones are met for its lead product Dalvance (dalbavancin).
- Full Acquisition
- Includes Earnout
- Payment Includes Cash for Equity
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.